

Special Issue

Genomic Instability and the DNA Damage Repair Response in Malignant Brain Tumors: Factors Underpinning Cancer Progression, Treatment Resistance, and Inter/Intra-Tumoral Heterogeneity

Message from the Guest Editor

Although comprising a small percentage (~2%) of all cancer types, malignant brain tumors affect both young and old, are often lethal, and account for a high degree of worldwide cancer mortality. Pediatric brain tumors, including gliomas and embryonal tumors, are the leading cause of cancer-related death among children and adolescents, while gliomas and meningiomas account for significant mortality in adults. Whereas precision medicine approaches are emerging, these tumors are usually treated with combinations of radiation; chemotherapy; and, more recently, immunotherapy. Recurrence of these malignant tumors is pervasive due to resistance to anticancer therapeutics, which may involve pronounced genomic instability or alteration in DNA damage repair responses elicited by chemoradiotherapy.

Guest Editor

Dr. Sachin Katyal

Department of Pharmacology and Therapeutics, University of Manitoba, Research Institute in Oncology and Hematology, CancerCare Manitoba; Winnipeg, MB, Canada

Deadline for manuscript submissions

closed (30 October 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51790

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)